Genzyme asks FDA to expand clofarabine's use to adults

11/24/2008 | American City Business Journals

Genzyme submitted an application seeking FDA approval to market clofarabine to treat adults with acute myeloid leukemia. The biotech firm already sells the drug under the brand Clolar for relapsed and treatment-resistant patients between ages 1 and 21 who suffer from acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR